XML 41 R26.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Summary of Significant Accounting Policies - Collaborative Research and Licensing Agreement (Details) | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | ---
Jun. 30, 2017 USD ($) | Mar. 31, 2017 USD ($) | Jul. 31, 2016 USD ($) | Jun. 30, 2016 USD ($) item | Sep. 30, 2015 USD ($) item | Dec. 31, 2014 USD ($) | Jul. 31, 2013 USD ($) item | Jan. 31, 2013 USD ($) item | Jun. 30, 2010 USD ($) | Dec. 31, 2017 USD ($) item | Sep. 30, 2017 USD ($) | Jun. 30, 2017 USD ($) | Mar. 31, 2017 USD ($) | Dec. 31, 2016 USD ($) | Sep. 30, 2016 USD ($) | Jun. 30, 2016 USD ($) | Mar. 31, 2016 USD ($) item | Dec. 31, 2015 USD ($) item | Mar. 31, 2014 USD ($) | Dec. 31, 2017 USD ($) item | Dec. 31, 2016 USD ($) item | Dec. 31, 2015 USD ($) | Dec. 31, 2012 USD ($) | Dec. 31, 2009 USD ($) item | Dec. 31, 2007 item
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  |  | $ 4,448,000,000 |  |  |  |  |  |  |  |  |  | $ 4,448,000,000 |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  | 10,941,000 | $ 7,090,000 | $ 13,340,000 | $ 4,340,000 | $ 6,440,000 | $ 7,821,000 | $ 66,007,000 | $ 7,252,000 |  |  | 35,711,000 | $ 87,520,000 | $ 27,762,000 |  |  |
Accounts receivable |  |  |  |  |  |  |  |  |  | 1,142,000 |  |  |  | 8,616,000 |  |  |  |  |  | 1,142,000 | 8,616,000 |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  | 94,400,000 |  |  |  | $ 103,400,000 |  |  |  |  |  | 94,400,000 | 103,400,000 |  |  |  |
Novartis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  |  | 2,410,000,000 |  |  |  |  |  |  |  |  |  | 2,410,000,000 |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,300,000 | 59,700,000 |  |  |  |
Amgen, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  |  | 1,647,500,000 |  |  |  |  |  |  |  |  |  | 1,647,500,000 |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 16,200,000 | 18,700,000 | 13,800,000 |  |  |
Novo Nordisk |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,700,000 | 2,900,000 |  |  |
MorphoSys |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  |  | 286,500,000 |  |  |  |  |  |  |  |  |  | 286,500,000 |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12,500,000 |  |  |  |  |
Alexion Pharmaceuticals, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  |  | 58,000,000 |  |  |  |  |  |  |  |  |  | 58,000,000 |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,000,000 | 6,000,000 | 8,500,000 |  |  |
CSL Limited |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,500,000 |  | 2,500,000 |  |  |
Collaboration And License Agreement | Novartis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment |  |  | $ 150,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,300,000 | $ 59,700,000 |  |  |  |
Accounts receivable |  |  |  |  |  |  |  |  |  | 1,100,000 |  |  |  |  |  |  |  |  |  | 1,100,000 |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  | 88,000,000 |  |  |  |  |  |  |  |  |  | 88,000,000 |  |  |  |  |
Collaboration And License Agreement | Novartis | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  |  |  | 2,400,000,000 |  |  |  |  |  |  |  |  |  | $ 2,400,000,000 |  |  |  |  |
Collaboration And License Agreement | Novartis | Global Discovery Program |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of programs where Company has the right to participate | item |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of Global discovery programs | item |  |  |  | 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of responsibility for development costs |  |  |  | 25.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of responsibility for commercialization costs |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of profits on net sales of the product |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of bispecific product candidates delivered | item |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |
Allocation of consideration to deliverables |  |  |  | $ 20,050,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And License Agreement | Novartis | Global Discovery Program | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of antibody targets for which bispecific technology applied | item |  |  |  | 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And License Agreement | Novartis | FC Licenses |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of bispecific product candidates delivered | item |  |  |  | 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Allocation of consideration to deliverables |  |  |  | $ 11,300,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And License Agreement | Novartis | FC Licenses | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of targets against which non-exclusive license is provided | item |  |  |  | 10 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And License Agreement | Novartis | Bispecific FC Technologies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of development stage products | item |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of previously identified products | item |  |  |  | 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research license term |  |  |  | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And License Agreement | Novartis | Bispecific FC Technologies | XmAb14045 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Allocation of consideration to deliverables |  |  |  | $ 27,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And License Agreement | Novartis | Bispecific FC Technologies | XmAb13676 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Allocation of consideration to deliverables |  |  |  | $ 31,400,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And License Agreement | Novartis | Bispecific FC Technologies | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of antibody targets for which bispecific technology applied | item |  |  |  | 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration And License Agreement | Amgen, Inc. | Discovery Program |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of bispecific product candidates delivered | item |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 |  |  |  |  |
Substituted candidates | item |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  |  |  |
Collaboration And License Agreement | Amgen, Inc. | Discovery Program | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of antibody targets for which bispecific technology applied | item |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 |  |  |  |  |  |  |
Collaboration And License Agreement | Novo Nordisk |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,500,000 |  |  |
Research license term |  |  |  |  |  | 2 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0 | $ 2,700,000 | $ 2,900,000 |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |
Milestone payment received |  |  |  |  |  | $ 1,600,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research term of revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 years |  |  |
Collaboration And License Agreement | MorphoSys |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment |  |  |  |  |  |  |  |  | $ 13,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment | $ 12,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12,500,000 | 0 | $ 0 |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |
License Agreement | Merck Sharp & Dohme Corp. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment |  |  |  |  |  |  | $ 1,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 500,000 | 100,000 | 100,000 | 100,000 |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  | 50,000 |  |  |  |  |  |  |  |  |  | 50,000 |  |  |  |  |
Annual maintenance fees |  |  |  |  |  |  | $ 500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of compounds | item |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option and license agreement | Alexion Pharmaceuticals, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment |  |  |  |  |  |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  |  |  |  | $ 66,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research license term |  |  |  |  |  |  |  | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,000,000 | 6,000,000 | 8,500,000 |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  | 83,000 |  |  |  |  |  |  |  |  |  | 83,000 |  |  |  |  |
Number of different target programs | item |  |  |  |  |  |  |  | 6 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual maintenance fees |  |  |  |  |  |  |  | $ 500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Annual maintenance fees payable during any extension of research term |  |  |  |  |  |  |  | 2,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Extension fee |  |  |  |  |  |  |  | $ 1,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research License and Option Agreement | Amgen, Inc. | Bispecific FC Technologies |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Milestone payment |  |  |  |  |  |  |  |  |  | 10,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
2009 Research License and Commercialization Agreement | CSL Limited |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 750,000 |
Potential milestone payment |  |  |  |  |  |  |  |  |  | 9,000,000 |  |  |  |  |  |  |  |  |  | 9,000,000 |  |  |  |  |
Milestone payment |  | $ 3,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research license term |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 years |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,500,000 | 0 | 2,500,000 |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |
Number of commercial options | item |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 |
Number of technologies to which research license is provided | item |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |
Research Licensee and Collaboration Agreement 2007 Agreement | Boehringer Ingelheim International GmbH |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research license term |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 years
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 | 0 |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |
Milestone payment received |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,200,000 |  |
Number of commercial options | item |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1
Number of compounds | item |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2
Research and License Agreement 2015 | Amgen, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront payment |  |  |  |  | $ 45,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payment |  |  |  |  | $ 1,700,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 16,200,000 | $ 18,750,000 | $ 13,750,000 |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  | $ 6,250,000 |  |  |  |  |  |  |  |  |  | 6,250,000 |  |  |  |  |
Number of different target programs | item |  |  |  |  | 6 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Research and License Agreement 2015 | Amgen, Inc. | CD38 Program |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Allocation of consideration to deliverables |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 13,750,000 |  |  |  |  |
Research and License Agreement 2015 | Amgen, Inc. | Discovery Program |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration research and licensing agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of previously identified products | item |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 | 3 |  |  |  |
Research license term |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 years |  |  |  |  |
Number of bispecific product candidates delivered | item |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 |  |  |  |
Allocation of consideration to deliverables |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 6,250,000 |  | $ 6,250,000 |  |  |  |  |
Previous targets which bispecific technology will be applied | item |  |  |  |  | 5 |  |  |  |  | 5 |  |  |  |  |  |  |  |  |  | 5 |  |  |  |  |
Additional research term |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 year |  |  |  |  |
Substituted candidates | item |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |
Number of delivered discover programs | item |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 |  |  |  |  |

X
- Definition Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the value established as the selling price of the significant unit of accounting used to allocate the consideration of the multiple-deliverable arrangement. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 25 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=68059916&loc=SL6750900-111635 + Details
Name: | us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the revenue earned during the period pertaining to collaborations, licenses and milestones. + References No definition available. + Details
Name: | xncr_CollaborationsLicensesAndMilestonesRevenue
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the number of antibody targets for which bispecific technology applied. + References No definition available. + Details
Name: | xncr_CollaborativeAgreementBispecificTechnologyAppliedNumberOfAntibodyTargets
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of delivery of targets for which bispecific technology applied. + References No definition available. + Details
Name: | xncr_CollaborativeAgreementBispecificTechnologyAppliedNumberOfTargetsDelivered
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of FC technology targets for which non-exclusive license is provided. + References No definition available. + Details
Name: | xncr_CollaborativeAgreementNonExclusiveLicenseProvidedNumberOfFcTechnologiesTargets
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of programs under the collaborative agreements. + References No definition available. + Details
Name: | xncr_CollaborativeAgreementNumberOfPrograms
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of profit on net sales of the product, if the company elects to participate in development. + References No definition available. + Details
Name: | xncr_CollaborativeAgreementPercentageOfProfitOnNetSales
Namespace Prefix: | xncr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of responsibility assumed for commercialization costs, if the company elects to participate in development. + References No definition available. + Details
Name: | xncr_CollaborativeAgreementPercentageOfResponsibilityAssumedForCommercializationCosts
Namespace Prefix: | xncr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the percentage of responsibility assumed for development costs, if the company elects to participate in development. + References No definition available. + Details
Name: | xncr_CollaborativeAgreementPercentageOfResponsibilityAssumedForDevelopmentCosts
Namespace Prefix: | xncr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the additional period for which research term may be extended under the collaborative agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementAdditionalResearchTerm
Namespace Prefix: | xncr_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the amount of nonrefundable upfront fees as provided under the collaboration agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementAnnualMaintenanceFees
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of annual maintenance fees payable during any extension of research term under the collaboration agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementAnnualMaintenanceFeesDuringExtensionOfResearchTerm
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of extension fees for extension of research term under the collaboration agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementExtensionFee
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of milestone payment received under the collaboration agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementMilestonePayment
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of nonrefundable upfront fees as provided under the collaboration agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementNonrefundableUpfrontFees
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the number of commercial options provided under the collaborative agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementNumberOfCommercialOptions
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of compounds. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementNumberOfCompounds
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of different target programs under the collaborative agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementNumberOfTargetPrograms
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of technologies to which research license is provided under the collaborative agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementNumberOfTechnologiesToWhichResearchLicenseProvided
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the research license term under the collaborative agreement. + References No definition available. + Details
Name: | xncr_CollaborativeArrangementResearchLicenseTerm
Namespace Prefix: | xncr_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of discover programs delivered. + References No definition available. + Details
Name: | xncr_NumberOfDeliveredDiscoverPrograms
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of development stage products that incorporate the company's bispecific Fc technology. + References No definition available. + Details
Name: | xncr_NumberOfDevelopmentStageProducts
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents information pertaining to the previously identified programs that can be substituted during the research term provided Amgen has not initiated non human primate studies + References No definition available. + Details
Name: | xncr_NumberOfPreviousIdentifiedProductsInWhichSubstitutionCanOccur
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of programs which the Company has the right to participate in the development and commercialization. + References No definition available. + Details
Name: | xncr_NumberOfProgramsRightToParticipate
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of substituted antibody candidates. + References No definition available. + Details
Name: | xncr_NumberOfSubstitutedAntibodyCandidates
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents information in which bispecific technology will be applied to previous targets + References No definition available. + Details
Name: | xncr_PreviousTargetsWhichBispecificTechnologyWillBeApplied
Namespace Prefix: | xncr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Period over which revenue is recognized under the agreement + References No definition available. + Details
Name: | xncr_RevenueRecognitionContractPeriod
Namespace Prefix: | xncr_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment received in associated with agreement as milestone was met. + References No definition available. + Details
Name: | xncr_RevenueRecognitionMilestoneMethodPayment
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of consideration that will be recognized upon full completion of milestones set forth in a collaborative agreement between two parties. + References No definition available. + Details
Name: | xncr_RevenueRecognitionMilestoneMethodPending
Namespace Prefix: | xncr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_NovartisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_AmgenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_NovoNordiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_MorphoSysMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_AlexionPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_CSLLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_CollaborationAndLicensingProgramsAxis=xncr_GlobalDiscoveryProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_CollaborationAndLicensingProgramsAxis=xncr_FcLicensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_CollaborationAndLicensingProgramsAxis=xncr_BispecificFcTechnologiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=xncr_Xmab14045ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=xncr_Xmab13676ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_CollaborationAndLicensingProgramsAxis=xncr_DiscoveryProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_MerckSharpAndDohmeCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_OptionAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_ResearchLicenseAndOptionAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_ResearchLicenseAndCommercialization2009AgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_ResearchLicenseeAndCollaborationAgreement2007AgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CounterpartyNameAxis=xncr_BoehringerIngelheimInternationalGmbhMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xncr_ResearchAndLicenseAgreement2015Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | xncr_CollaborationAndLicensingProgramsAxis=xncr_Cd38ProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |